

CSL Limited
2011/12 Half Year Result

22 February 2012

Disclaimer

Forward looking statements

The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL's financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "target," "may," "assume," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding whether and when to approve our products as well as their decisions regarding labeling and other matters that would affect the commercial potential of our products; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement or access; litigation or government investigations, including legal costs, settlement costs and the risk of adverse decisions or settlements; and CSL's ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward looking statements.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Financials

Reported total sales \$2.2 billion, up 13% at Constant Currency¹ (CC)

Reported EBIT \$607 million, up 14% at CC

Reported NPAT \$483 million, down 3%

- *Up 16% at CC*
- *Foreign currency headwind \$95 million*

Reported EPS 92.2 cents, up 1%

R&D investment \$161 million, up 16% at CC

Cashflow from operations \$522 million, up 28%

Strong balance sheet - cash \$1,300m, borrowings \$1,278m

\$900m on market share buyback ~20% complete, \$181m spent

Interim dividend increased to 36 cents (unfranked)

1. Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note for further detail.

Operational Highlights

Immunoglobulin sales up 21% at constant currency

- Strong demand across product range
- Privigen® - European Phase III study in CIDP completed

Specialty products up 20% at constant currency

- RiaSTAP™ - Ph III peri-operative bleeding study initiated in EU
- Berinert® - US & EU approval for self administration

Recombinant haemophilia pipeline

- rIX-FP - Commencement of phII/III pivotal study
- rVIIa-FP – US FDA grants orphan drug designation
- rVIII-SingleChain – first patient recruited for trial

Gardasil* recommendation for boys in Australia, Canada, US


Investment in facilities expansion

Capital Management

- ~\$800m in new lines of credit
- US\$750m private placement
- Buyback ~20% complete

* GARDASIL is a trademark of Merck & Co. Inc.

Global Revenue* \$2.3 Billion for 1H12



* Revenue based on customer location

Outlook for FY2012

@ 10/11 exchange rates

Guidance upgraded

- Net profit after tax¹ ~\$1,060 million
- NPAT growth ~13% (*previously ~10%*)
- EPS expected to exceed NPAT growth driven by past and current capital management initiatives²

US Dollar Reporting

- Intention to move to reporting in US dollars for the 2012/13 financial year

Outlook statements are subject to:

Material price and volume movements on core plasma products, competitor activity, changes in healthcare regulations and reimbursement policies, royalties arising from the sale of Human Papillomavirus vaccine, implementation of the Company's influenza strategy and plasma therapy life cycle management strategies, enforcement of key intellectual property, regulatory risk, litigation, the effective tax rate and foreign exchange movements.

1. See appendix for foreign exchange sensitivity table
2. CSL reserves the right to suspend, terminate or extend the buyback at any time

Human Health Business Unit Performance

- CSL Behring
- Other Human Health
 - CSL Biotherapies and CSL Research & Development
- Intellectual Property Licensing

CSL Behring

Product sales US\$1,883m up 17% (+ 13% at CC)

Immunoglobulin

- Strong demand across IG product range
- Privigen® - European Phase III study in CIDP completed
- Hizentra® (IgPro20 sc) - Broader approvals in EU and Canada


Specialty Products

- Berinert® - US & EU approval for self administration
- Changing paradigm for peri-operative bleeding treatment


Facilities Development

- Privigen capacity expansion commenced at Broadmeadows
- Bern - IgLab Module 2 online increasing capacity
- Plasma collection fleet – investing in efficiencies
- Albumin and base fractionation capacity expansion at Kankakee

CSL Behring – Product sales up 13% in CC terms



Immunoglobulins



Highlights

Up 21% in CC terms

Growth

Volume

- US, Canada, UK, France and Germany

SCIG demand


- New patients
- Migration to Hizentra[®] from Vivaglobin[®]

Other growth drivers

- Sales mix
- Rhophylac[®] growth
- Competitor returning

Albumin

US\$M



Sales for the 6 month period


Highlights

Up 14% in CC terms

Demand growth in Asia

* CSL Behring albumin sold in Asia by CSL Biotherapies

Haemophilia



Sales for the 6 month period

Highlights

Up 4% in CC terms

PdFVIII


- ITT patient growth in Europe
- Beriate[®] demand growth in Russia, Poland & Brazil

Helixate[®]

- Demand growth in Canada

Specialty Products

US\$M



Sales for the 6 month period

Highlights

Up 20% in CC terms


Peri-operative Bleeding

- Haemocomplettan[®] / RiaSTAP[®] changing treatment paradigm for Peri-Operative Bleeding
- Corifact[®] - Launch in US
- Beriplex[®] - Launch in Canada

Other

- Berinert[®] P – US self administration approval

Other Human Health – CSL Biotherapies



Highlights

Up 13% in CC terms

Albumin demand growth in Asia

Broadmeadows plasma therapy sales \$125m

Influenza sales \$93m following solid US and European demand

Gardasil* sales growth in Australian NIP and private markets

Biotech facility on track for opening in FY2013

* Gardasil is a trademark of Merck & Co. Inc

CSL Behring albumin sold in Asia by CSL Biotherapies

CSL Intellectual Property Licensing

Segment Revenue \$80m

HPV royalties \$61m

Sale of MPS IP \$18m

Gardasil*

- Recommendation for boys in Australia, Canada, US
- Label expansion to cover anal cancer in Australia
- Japanese rollout commenced

ISCOMATRIX® adjuvant

- Major partners continue to advance vaccine programs and license additional fields

CAM3001 (GM-CSFR α)

- Licensee Medimmune/AstraZeneca completed Phase II study in Rheumatoid Arthritis
- Clinical effect and safety profile support further development

R&D Update

rIX-FP (rec fusion protein linking factor IX with albumin)

- Ph I data presented at GTH
- Commencement of pHII/III pivotal study in Jan 2012

rVIIa-FP

- US orphan drug status

rVIII-SingleChain

- 1st patient recruited for phase I trial

RiaSTAP™ (Fibrinogen)

- Ph III peri-operative bleeding study initiated in EU Dec 2011

Cytogam® (Cytomegalovirus immune globulin)


- NIH partnership for congenital CMV infection

Biostate®

- Dossier filed with European Medicines Agency

Financial Detail

1H 2012 Net Profit after Tax up 16% at CC



FX impact

Reported NPAT	\$483m
Foreign currency*	-ve \$95m
NPAT at constant currency	<u>\$578m</u>


Notable items

MPS royalty

Competitor returning

Southern European debtors

CSL Behring - Reported EBIT Margin



Notable items

- Foreign Exchange
 - Weakening USD against the Swiss Franc
- Sales mix
 - Sales growth of IG into European countries
- Southern European debtor provisioning

Financial Discipline

	1H11	1H12
Cashflow from operations	\$408m	\$522m
Capital Investment	\$84m	\$142m
Cash cycle - days	148	139
Cash conversion %	83.7	97.3

- Balance Sheet Strength -



Capital Management

Cash on hand \$1.3 billion

Debt Refinancing

- US\$750 million private placement in the US
- ~\$800 million in new lines of credit
 - *Undrawn \$450 million*

On Market Buyback

\$900m on-market share buyback*

Commenced 18 October 2011

- 12 month window to complete

As at 22 February 2012

- ~5.8 million shares repurchased for \$181 million
- ~20% complete

* CSL reserves the right to suspend, terminate or extend the buyback at any time


FX Impact on FY2012 Guidance*

Foreign exchange (post tax)

	FY12 Est.
Translation	~ \$ (30)m
Transaction	~ <u>\$ (85)m</u>
Total	~ \$(115)m

Net profit after tax outlook


NPAT FY2012 at constant currency <i>Growth ~13% on FY2011 profit (previously ~10%)</i>	~\$1,060m
Est. foreign currency NPAT impact	~\$(115)m
NPAT FY2012 at current rates	~ <u>\$945m</u>



US Dollar Reporting

- Full year impact
- See appendix for foreign exchange sensitivity table

CSL Growth Strategy



R&D capabilities - Financial strength



Appendix

Group Results

Australian dollars

Six months ended December \$ Millions	Dec 2010 Reported	Dec 2011 Reported	Dec 2011 CC ¹	Change %
Sales	2,116	2,221	2,401	13.4%
Other Revenue / Income	56	88	95	
Total Revenue / Income	2,172	2,309	2,496	
Earnings before Interest, Tax, Depreciation & Amortisation	719	689	811	12.9%
Depreciation/Amortisation	83	82	85	
Earnings before Interest and Tax	636	607	726	14.2%
Net Interest Expense / (Income)	(11)	-	1	
Tax Expense	147	124	148	
Net Profit	500	483	578	15.5%
Interim Dividends (cents)	35.00	36.00		
Basic EPS (cents)	91.5	92.2		

¹ Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note for further detail.



Group Results

Restated in US Dollars¹

Six months ended December US\$ Millions	Dec 2010 Reported	Dec 2011 Reported	Change %
Sales	1956	2,324	18.8%
Other Revenue / Income	52	91	
Total Revenue / Income	2,008	2,414	
Earnings before Interest, Tax, Depreciation & Amortisation	664	720	8.4%
Depreciation/Amortisation	76	86	
Earnings before Interest and Tax	588	634	7.8%
Net Interest Expense / (Income)	(10)	-	
Tax Expense	135	130	
Net Profit	463	504	8.9%

¹ The Group's result in USD has been prepared by translating the results of all entities in the Group into US dollars using average reporting period exchange rates.

CSL Behring Sales

US Dollars

Six months ended December	1H11 USD\$M	1H12 USD\$M	1H12 USD\$M CC	Change %
rFVIII	238	257	248	4%
pdCoag	258	280	269	4%
Albumin (excludes Asian sales)	143	157	152	6%
Immunoglobulins	687	853	834	21%
Specialty Products	248	315	297	20%
- <i>Wound healing</i>	50	54	50	--%
- <i>Peri-operative bleeding</i>	91	126	118	30%
- <i>Other specialty products</i>	108	136	131	21%
Total Product Sales	1,574	1,862	1,800	14%
<i>Other sales (mainly plasma)</i>	37	22	16	-57%
<i>Total Sales</i>	<i>1,611</i>	<i>1,884</i>	<i>1,816</i>	<i>13%</i>



Foreign Exchange Sensitivity 2H12

Translation - Ready Reckoner

Sensitivity to 1% movement in key currency pairs

	Current Rates	1% change
AUD/USD*	1.07	+/- \$1.0m
AUD/EUR	0.81	+/- \$1.3m
AUD/CHF	0.98	+/- \$2.9m

- Table shows full 6 months impact
- Impact to be calculated from NPAT guidance at current FX rates of ~\$945m

* Includes HPV Royalties

Notes

Constant currency removes the impact of exchange rate movements to facilitate comparability by restating the current year's results at the prior year's rates. This is done in two parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than Australian Dollars at the rates that were applicable to the prior year ("translation currency effect") and comparing this with the actual profit of those entities for the current year; and b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior year ("transaction currency effect") and comparing this with the actual transaction recorded in the current year. The sum of translation currency effect and transaction currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.

Summary

Reported Net Profit after Tax	\$483.3m
Translation Currency Effect (1)	\$ 4.1m
Transaction Currency Effect (2)	\$ 90.6m
Constant Currency Net Profit after Tax *	\$578.0m

1. Translation Currency Effect \$4.1m

Average Exchange rates used for calculation in major currencies were as follows:

	Six months to	
	Dec 11	Dec 10
AUD/USD	1.05	0.93
AUD/EUR	0.75	0.71
AUD/CHF	0.89	0.94

2. Transaction Currency Effect \$90.6m

Transaction currency effect is calculated by reference to the applicable prior year exchange rates. The calculation takes into account the timing of sales both internally within the CSL Group (ie from a manufacturer to a distributor) and externally (ie to the final customer) and the relevant exchange rates applicable to each transaction.

* Constant Currency Net profit after Tax has not been audited or reviewed in accordance with Australian Auditing Standards